Euroapi Past Earnings Performance
Past criteria checks 0/6
Euroapi's earnings have been declining at an average annual rate of -72.5%, while the Pharmaceuticals industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 3.7% per year.
Key information
-72.5%
Earnings growth rate
-72.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 16.3% |
| Revenue growth rate | 3.7% |
| Return on equity | -20.4% |
| Net Margin | -18.6% |
| Next Earnings Update | 31 Jul 2024 |
Recent past performance updates
Recent updates
Euroapi (EPA:EAPI) Seems To Be Using A Lot Of Debt
Apr 10
Little Excitement Around Euroapi S.A.'s (EPA:EAPI) Revenues As Shares Take 31% Pounding
Mar 03Euroapi S.A. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
Mar 02A Look At The Fair Value Of Euroapi S.A. (EPA:EAPI)
Dec 21Analysts Are Updating Their Euroapi S.A. (EPA:EAPI) Estimates After Its Half-Yearly Results
Aug 04Is Euroapi S.A. (EPA:EAPI) Trading At A 49% Discount?
Aug 02Euroapi S.A.'s (EPA:EAPI) Subdued P/S Might Signal An Opportunity
Jun 16An Intrinsic Calculation For Euroapi S.A. (EPA:EAPI) Suggests It's 37% Undervalued
Jan 25Euroapi S.A.'s (EPA:EAPI) Intrinsic Value Is Potentially 38% Above Its Share Price
Oct 15Statutory Profit Doesn't Reflect How Good Euroapi's (EPA:EAPI) Earnings Are
Sep 09Revenue & Expenses BreakdownBeta
How Euroapi makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,019 | -190 | 134 | 30 |
| 30 Sep 23 | 1,006 | -79 | 135 | 27 |
| 30 Jun 23 | 994 | 31 | 137 | 24 |
| 31 Mar 23 | 987 | 8 | 133 | 23 |
| 31 Dec 22 | 981 | -15 | 129 | 22 |
| 30 Sep 22 | 962 | -3 | 120 | 20 |
| 30 Jun 22 | 944 | 10 | 110 | 18 |
| 31 Mar 22 | 918 | 1 | 100 | 18 |
| 31 Dec 21 | 893 | -8 | 90 | 17 |
| 31 Dec 20 | 945 | -6 | 71 | 20 |
| 31 Dec 19 | 916 | 3 | 66 | 16 |
Quality Earnings: EAPI is currently unprofitable.
Growing Profit Margin: EAPI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EAPI is unprofitable, and losses have increased over the past 5 years at a rate of 72.5% per year.
Accelerating Growth: Unable to compare EAPI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EAPI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: EAPI has a negative Return on Equity (-20.45%), as it is currently unprofitable.